PRIVILEGED & CONFIDENTIAL — ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP
MEMORANDUM
TO: Leonard Cross, Sylvia Hartwell, Garrett Simmons — Calderwood & Harkness LLP
FROM: Leila Nazari — Calderwood & Harkness LLP
DATE: September 30, 2022
RE: Analysis of Penterra Biopharma International DAC Board Minutes — 42 Meetings (2017–2020)
MATTER NO.: 1018-00009
CLIENT: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)
Right-click to update Table of Contents
I. Purpose and Executive Summary
This memorandum catalogues and analyzes the forty-two (42) board meetings of Penterra Biopharma International DAC ("PBI") held in Dublin, Ireland during calendar years 2017 through 2020. The purpose of this analysis is to demonstrate the substantive governance, decision-making authority, and operational control exercised by PBI's board of directors in connection with its role as the intellectual property–holding company and commercial principal for non-Americas commercialization of products developed by or under the auspices of Penterra Pharmaceuticals Corp. ("PPC"). This analysis is prepared in anticipation of litigation and for use in the ongoing IRS examination of PPC for tax years 2017 through 2020, Exam Team ID LB&I-NE-TP-2022-00641.
The relevance of this analysis to PPC's defense posture cannot be overstated. The IRS examination team has challenged the transfer pricing methodology used in PPC's Irish IP-holding structure, including an assertion — articulated most prominently in the examination team's preliminary position paper circulated on July 18, 2022 — that PBI lacked sufficient economic substance to justify its role as a participant in the cost-sharing arrangement ("CSA") and as the owner of valuable intangible property rights outside the Americas. Central to the IRS's theory is the contention that key DEMPE (Development, Enhancement, Maintenance, Protection, and Exploitation) functions with respect to the intangible property at issue remained in the United States and were performed by PPC personnel, with PBI serving as a mere conduit or shell entity whose governance and decision-making were directed from PPC's headquarters in Princeton Junction, New Jersey. The board minutes analyzed herein are central evidence rebutting this position.
Our analysis reveals the following summary findings:
Over the 2017–2020 period, PBI's board of directors convened a total of 42 times, comprising both regular quarterly meetings and special sessions called to address significant transactions, pricing decisions, market entry determinations, regulatory milestones, and budgetary approvals. All 42 meetings were held physically in Dublin, Ireland, at PBI's registered offices located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4. While certain meetings during the latter portion of 2020 transitioned to a hybrid or video-assisted format due to restrictions arising from the COVID-19 pandemic, a quorum of directors was physically present in Dublin for each such meeting.
The minutes of these 42 meetings document substantive deliberation and decision-making across a broad range of commercial, regulatory, financial, and operational matters, including but not limited to: (i) pricing strategy across 68 non-Americas country markets for PBI's four principal product families; (ii) market entry and market exit decisions; (iii) regulatory submission approvals and strategic prioritization of filings with the European Medicines Agency ("EMA") and local-country regulatory authorities; (iv) capital expenditure approvals totaling approximately €47.2 million in cumulative regulatory spending over the four-year period; (v) supply-chain management and oversight of PBI's contract manufacturing relationship with Penterra Manufacturing Ireland Ltd. ("PMI"); and (vi) significant commercial transactions, including the negotiation and execution of distribution agreements with third-party distributors in multiple territories.
Critically, the minutes demonstrate that PBI's board exercised genuine, independent authority over these matters rather than merely rubber-stamping directives issued by PPC's U.S.-based management. The records reflect instances of deliberation among board members, evaluation of alternatives, exercise of judgment on pricing and market strategy, and, in certain documented instances, decisions that diverged from or modified recommendations presented by PPC personnel. This pattern of active governance is fundamentally inconsistent with the IRS's characterization of PBI as a nominal entity lacking economic substance.
The board minutes reviewed herein were obtained in their entirety from PBI's Managing Director, Aidan Naughton, and were cross-referenced against PBI's corporate secretary files maintained at the Dublin office. Complete copies of all 42 sets of minutes were produced to the IRS in response to Information Document Request ("IDR") No. 9, the production of which was completed on September 12, 2022.
II. Background — PBI Corporate Governance Structure
A. Entity Overview
Penterra Biopharma International DAC ("PBI") is a Designated Activity Company organized and existing under the laws of Ireland. PBI's registered office is located at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI is registered with the Irish Revenue Commissioners under Tax Reference Number 3218764T and is subject to Irish corporation tax on its worldwide income. PBI was incorporated on April 12, 2012, and commenced commercial operations effective July 1, 2012, concurrent with the effectiveness of the cost-sharing arrangement described below.
PBI is 100% owned by Penterra Holdings Luxembourg S.à r.l. ("PHL"), a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg, with its registered office at 14 rue Aldringen, L-1118 Luxembourg, and registered with the Luxembourg Trade and Companies Registry (Registre de Commerce et des Sociétés) under number RCS B 168452. PHL is, in turn, 100% owned by Penterra Pharmaceuticals Corp. ("PPC"), a Delaware corporation headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550, and publicly traded on the Nasdaq Stock Market under the ticker symbol PPCA. For U.S. federal income tax purposes, PHL is treated as a disregarded entity pursuant to a check-the-box election filed on Treasury Form 8832, effective upon its formation. Accordingly, for U.S. tax purposes, PBI is treated as a directly-owned controlled foreign corporation ("CFC") of PPC.
PBI serves as the intellectual property–holding company and commercial principal for non-Americas commercialization of PPC products. In this capacity, PBI performs two primary functions:
First, PBI is a controlled participant in a qualified cost-sharing arrangement (the "CSA"), effective July 1, 2012, entered into with PPC pursuant to Treasury Regulation § 1.482-7. Under the CSA, PBI co-funds research and development costs incurred by PPC and its affiliates in exchange for the right to exploit certain intangible property outside the Americas region (defined in the CSA as North America, Central America, South America, and the Caribbean). PBI's cost-sharing payments during the 2017–2020 period ranged from approximately $186.15 million (2017) to approximately $255.52 million (2020), reflecting PBI's share of total R&D costs based on reasonably anticipated benefit ("RAB") calculations updated annually.
Second, PBI holds exclusive licenses to certain legacy pharmaceutical compounds — those whose development was substantially completed prior to the effectiveness of the CSA on July 1, 2012 — under a license agreement with PPC dated July 1, 2012. Under this agreement, PBI pays PPC a royalty of 4.5% of net sales of legacy compounds in non-Americas territories.
PBI's employee headcount has grown significantly since its incorporation. At the time of its establishment in 2012, PBI had 52 employees based in Dublin. By December 31, 2020, PBI employed 185 individuals, all based in Ireland, covering the following functional areas: regulatory affairs, medical affairs, commercial strategy, market access, supply-chain management, quality assurance, finance, legal, human resources, and general administrative functions. PBI's growth in headcount over this period reflects its expanding operational responsibilities and the increasing scale of its non-Americas commercial operations.
PBI's Managing Director is Aidan Naughton, who has served in that capacity since PBI's establishment in 2012. Mr. Naughton is an Irish citizen resident in Dublin and holds overall executive responsibility for PBI's operations, reporting to PBI's board of directors. Mr. Naughton also serves as chair of the PBI board.
B. Board Composition (2017–2020)
During the 2017–2020 period, PBI's board of directors comprised a mix of Ireland-resident directors and directors appointed by PPC, the ultimate parent company. Importantly for purposes of the economic substance analysis, the board maintained a majority of Ireland-based directors throughout the period under review. This composition ensured that the board's decision-making reflected local governance, market knowledge, and independent judgment exercised by individuals resident in and familiar with PBI's operating environment.
Mr. Naughton served as both Managing Director and chair of the board throughout the period. Additional directors included both senior PBI executives resident in Ireland and certain PPC-appointed directors who participated in board deliberations. The identities and tenures of all directors are reflected in the individual meeting minutes and in PBI's filings with the Companies Registration Office in Ireland. Board meetings were supported by PBI's local corporate secretary, who maintained the minutes and records in accordance with PBI's articles of association and applicable provisions of the Irish Companies Act 2014.
All board meetings were conducted in accordance with the procedural requirements set forth in PBI's articles of association, including requirements for notice, quorum, agenda circulation, and resolution recording. The corporate secretary ensured that proper records were maintained for each meeting, including signed minutes, copies of presentations and reports considered by the board, and records of all resolutions adopted.
C. Meeting Cadence
PBI's board maintained a regular meeting cadence throughout the 2017–2020 period, convening for quarterly meetings typically held in March, June, September, and December of each year. In addition to these regular quarterly meetings, the board convened special meetings as needed to address significant transactions, time-sensitive market entry or exit decisions, pricing approvals requiring immediate attention, regulatory milestones, and annual budget approvals.
Over the four-year period, the board met a total of 42 times, averaging 10.5 meetings per year. This frequency of board meetings substantially exceeds the minimum statutory requirements under Irish company law and reflects an active governance commensurate with PBI's role as a significant commercial enterprise managing operations across 68 country markets. The breakdown by year is as follows:
All 42 meetings were held physically in Dublin at PBI's registered offices at Sandyford Business Park. During the latter portion of 2020, following the imposition of public health restrictions in Ireland in response to the COVID-19 pandemic, certain meetings were conducted in a hybrid format, with some participants joining via video conference. However, in each such instance, a quorum of directors — including the chair, Mr. Naughton — was physically present at the Dublin offices, ensuring that the meetings were properly constituted under PBI's articles of association and that the locus of decision-making remained in Ireland.
D. Legal Significance for Transfer Pricing Defense
The board minutes analyzed in this memorandum bear directly on several legal standards central to PPC's transfer pricing defense.
Under Treasury Regulation § 1.482-7, which governs qualified cost-sharing arrangements, a controlled participant must exercise control over, and bear the risks associated with, the development, enhancement, maintenance, protection, and exploitation of cost-shared intangibles. The board minutes demonstrate that PBI exercised such control with respect to the non-Americas exploitation rights that form the subject of its CSA participation. The minutes document the PBI board's active oversight of regulatory strategy, pricing, market access, and commercial operations — all of which are core DEMPE functions — in a manner consistent with PBI's status as a genuine controlled participant rather than a passive funding entity.
Under Treasury Regulation § 1.482-1(d), which articulates the arm's-length standard, the determination of whether controlled transactions are at arm's length requires an assessment of the functions performed, assets used, and risks assumed by each party. The board minutes provide contemporaneous evidence of the functions PBI performed and the risks it bore, including commercial risk across 68 country markets, regulatory risk associated with obtaining and maintaining marketing authorizations, foreign-exchange risk, supply-chain risk, and competitive risk. This evidence supports the conclusion that PBI's transfer pricing arrangements — including the 4.5% legacy IP royalty and the CSA cost-sharing ratios — reflect arm's-length terms between entities operating with genuine economic substance.
The OECD Transfer Pricing Guidelines, as revised in 2017 and further updated in 2022, provide in Chapter VI detailed guidance on the analysis of transactions involving intangible property, including the DEMPE framework. The Guidelines emphasize that the entity claiming entitlement to returns from intangibles must exercise control over the relevant DEMPE functions and possess the capability and actual performance of those functions. The PBI board minutes, documenting active governance and decision-making over Enhancement, Maintenance, Protection, and Exploitation of IP in PBI's territory, are directly responsive to this framework.
Finally, the active board governance documented in the minutes is a hallmark of genuine economic substance under the economic substance doctrine, which the IRS has invoked as a basis for its challenge. The regularity, substantive content, and independent character of PBI's board proceedings are inconsistent with the characterization of PBI as a sham or conduit entity.
III. Methodology of Analysis
The analysis presented in this memorandum was conducted as follows:
All 42 sets of board minutes spanning the period from January 1, 2017 through December 31, 2020 were reviewed in their entirety by the undersigned and by associates in the Calderwood & Harkness tax controversy practice group. The minutes were obtained from PBI's Managing Director, Aidan Naughton, and independently verified against PBI's corporate secretary files. Each set of minutes was reviewed in its original form, as maintained in PBI's corporate records.
Each meeting was catalogued by the following attributes: (i) date of the meeting; (ii) location of the meeting (all 42 meetings took place in Dublin, Ireland); (iii) attendees, including directors present, directors absent (if any), and non-director participants such as PBI management, external advisors, and PPC personnel who presented information to the board; and (iv) agenda items addressed during the meeting.
Key decisions reflected in the minutes were identified and classified into the following ten categories, which correspond to the principal areas of PBI's operational and commercial activity:
1. Pricing decisions — including the setting, adjustment, and review of product pricing across non-Americas country markets;
2. Market entry and market exit decisions — including the approval of entry into new country markets and decisions to scale back or exit underperforming markets;
3. Regulatory submissions and approvals — including the authorization of regulatory filing strategies, budget allocations for regulatory expenditures, and review of regulatory milestones;
4. Capital expenditure approvals — including approvals for Dublin office infrastructure, IT systems, regulatory compliance tools, and digital platforms;
5. Supply-chain and contract manufacturing oversight — including review of the performance of PMI under the cost-plus 8% contract manufacturing agreement, quality assurance, and capacity planning;
6. Budgeting and financial planning — including annual operating budget approvals, mid-year reforecasts, and year-end financial statement approvals;
7. Risk management — including discussions of foreign-exchange risk, market-access risk, regulatory risk, competitive risk, and pandemic-related risks;
8. Personnel and organizational matters — including headcount approvals, key hires, organizational restructuring, and talent development;
9. CSA-related decisions — including annual cost-sharing percentage determinations, CSA payment reconciliations, and review of reasonably anticipated benefit projections; and
10. Other material decisions — including treasury operations, Knowledge Development box compliance, distribution agreement negotiations, and other matters not falling within the above categories.
Where available, supporting documentation referenced in the board minutes — including management presentations, financial analyses, market assessments, regulatory dossier summaries, approval forms, and draft resolutions — was obtained and cross-referenced against the minutes to verify the accuracy and completeness of the minutes' description of matters considered by the board. Not all supporting documentation was available for every meeting; however, a substantial body of supporting materials has been located and catalogued as described in Appendix C to this memorandum.
Particular attention was paid throughout the review to evidence bearing on the central question in the IRS examination: whether PBI's board exercised genuine, independent decision-making authority over the matters within its purview, or whether the board merely ratified decisions made by PPC personnel in the United States. This question goes to the heart of the IRS's economic substance challenge and the DEMPE analysis. Accordingly, the review focused not only on the substantive content of the decisions documented in the minutes, but also on the process of decision-making reflected therein, including the nature and extent of board deliberation, the presentation and evaluation of alternatives, the exercise of judgment by Ireland-resident directors, and instances where the board's decisions diverged from or modified recommendations presented by PPC-affiliated individuals.
IV. Meeting-by-Meeting Catalogue
The following sections provide a detailed catalogue of each of the 42 board meetings held during the 2017–2020 period, organized by calendar year. For each meeting, we identify the date, location, attendees, principal agenda items, and key decisions or resolutions adopted. Where particular decisions are of heightened significance to the transfer pricing defense, additional commentary is provided.
A. 2017 Meetings (10 Meetings)
Meeting 1 — Q1 Regular Meeting (March 16, 2017)
Date: March 16, 2017
Location: 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland
Attendees: Full board present, including chair Aidan Naughton; PBI CFO and Head of Commercial Strategy in attendance as management observers; PBI corporate secretary present.
Agenda Items:
• Review of FY 2016 non-Americas financial performance, including revenue, gross margin, operating income, and comparison to budgeted targets
• Presentation and approval of 2017 operating budget for PBI
• Pricing review for Veritaxol (PBI's lead revenue-generating product) across 12 European markets
• Discussion of launch preparations for Imvara in Asia-Pacific territories, including regulatory readiness assessment and market-access strategy
• Approval of 2017 regulatory filing expenditure budget
• Review of CSA cost-sharing calculation methodology and projected 2017 payment
• Corporate secretary's report on compliance matters
Key Decisions:
• The board approved PBI's 2017 operating budget, which included a projected cost-sharing payment of $186.15 million, representing 38.2% of total anticipated R&D costs of $487.3 million. The cost-sharing percentage was determined based on updated reasonably anticipated benefit ("RAB") calculations prepared by PBI's finance team and reviewed by the board. The board discussed the methodology underlying the RAB calculation, including market growth projections for non-Americas territories, and approved the percentage after deliberation.
• The board approved pricing adjustments for Veritaxol in 12 European markets. The pricing review was conducted by PBI's commercial strategy team in Dublin, which presented a detailed market-by-market analysis incorporating local competitive dynamics, reimbursement frameworks, health technology assessment outcomes, and projected demand elasticity. The board considered the recommendations and approved specific price points for each of the 12 markets, including certain adjustments that reflected local conditions diverging from U.S. pricing levels.
• The board authorized €8.5 million in regulatory budget allocation for 2017, covering planned submissions to the EMA and local-country regulatory authorities for product line extensions and new indications.
Meeting 2 — Special Meeting (April 27, 2017)
Date: April 27, 2017
Location: 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland
Attendees: Quorum of board present, including chair Aidan Naughton; PBI Head of Asia-Pacific Commercial Operations and Head of Distribution Partnerships in attendance to present.
Agenda Items:
• Evaluation and approval of market entry into three new Asia-Pacific country markets
• Review of distribution partner candidates for Southeast Asian territories
• Establishment of negotiation parameters for local distribution agreements
• Risk assessment for new market entries, including regulatory, currency, and political considerations
Key Decisions:
• The board evaluated detailed market assessments prepared by PBI's commercial team for three proposed new country markets in the Asia-Pacific region. The assessments covered market size, patient population, competitive landscape, regulatory pathway and estimated timeline for marketing authorization, distribution infrastructure, and projected revenue and profitability. After deliberation, the board approved entry into all three markets, subject to satisfactory completion of due diligence on distribution partners and finalization of regulatory submission plans.
• The board reviewed presentations on four candidate distribution partners for the Southeast Asian territories, evaluating each candidate's market coverage, commercial capabilities, regulatory compliance track record, and financial stability. The board selected the preferred distribution partner for each territory and authorized PBI's Head of Distribution Partnerships to negotiate definitive distribution agreements within commercial terms and parameters approved by the board.
• Notably, the minutes reflect that the board independently evaluated and approved distribution partner candidates and set commercial terms without directives from PPC's U.S. headquarters. While PPC's global commercial team had provided market intelligence data that informed the assessments, the ultimate selection of partners and the establishment of negotiation parameters were decisions of the PBI board. This is significant evidence of PBI's independent commercial judgment.
Meeting 3 — Q2 Regular Meeting (June 22, 2017)
Date: June 22, 2017
Location: 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland
Attendees: Full board present; PBI management team in attendance, including Managing Director, CFO, Head of Regulatory Affairs, and Head of Supply Chain.
Agenda Items:
• Review of H1 2017 financial performance against budget, including product-by-product revenue analysis
• Veritaxol non-Americas revenue tracking and variance analysis
• Imvara non-Americas revenue tracking and launch status in newly approved markets
• Supply-chain review and performance assessment for PMI (Penterra Manufacturing Ireland Ltd., Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29), including review of manufacturing output, quality metrics, and compliance with the cost-plus 8% manufacturing agreement
• Review of Cerulon rare-disease pipeline for non-Americas territories, including regulatory and commercial development status
• Update on distribution agreement negotiations authorized at Meeting 2
Key Decisions:
• The board reviewed H1 2017 performance data indicating that Veritaxol non-Americas net sales were tracking approximately 3.2% above budget, while Imvara was tracking approximately 1.8% below budget due to delays in regulatory approval in two EMEA markets. The board discussed remedial actions for the Imvara shortfall, including acceleration of regulatory interactions and enhanced market-access engagement.
• The board reviewed PMI's manufacturing performance report, noting that PMI (which employed approximately 560 employees at the time) had met quality and output targets for the quarter. The board discussed capacity planning considerations in light of projected Veritaxol demand growth and authorized PBI management to engage in discussions with PMI regarding potential capacity expansion.
• The board received a presentation on Cerulon's regulatory status in non-Americas territories. Cerulon, a rare-disease therapy, was in earlier stages of non-Americas commercialization, and the board discussed filing strategies and market-access considerations. The board approved the engagement of local regulatory consultants in three EMEA markets to support planned submissions.
Meetings 4–10 — Remaining 2017 Meetings
The remaining seven meetings held during 2017 (Meetings 4 through 10) are summarized below by principal topics addressed. A complete listing of dates, attendees, and key resolutions for each meeting is provided in Appendix A.
Meeting 4 — Special Meeting (July 2017): The board approved additional pricing decisions for Veritaxol and Imvara across specific country markets in the EMEA region, based on updated competitive intelligence and health technology assessment outcomes. The board also reviewed and approved revised commercial terms for two distribution agreements in the Asia-Pacific region.
Meeting 5 — Special Meeting (August 2017): The board addressed regulatory submission approvals for Imvara in four EMEA markets. The Head of Regulatory Affairs presented detailed dossier readiness assessments for each market, and the board approved the filing timeline and associated expenditure, contributing to the cumulative €47.2 million regulatory spend documented over the 2017–2020 period.
Meeting 6 — Q3 Regular Meeting (September 2017): The board conducted a comprehensive nine-month financial review, including product-by-product revenue analysis, operating expense review, and reforecast of the 2017 budget. The board also reviewed the status of the Dublin office infrastructure, approving capital expenditure for improvements to PBI's approximately 18,000 square feet of office space at Sandyford Business Park.
Meeting 7 — Special Meeting (October 2017): The board addressed CSA cost-sharing payment reconciliation matters and reviewed the Q3 2017 reasonably anticipated benefit calculation. The board also received a treasury operations update, including the status of PBI's banking relationship with Glenmore Bank Ireland plc and the management of cash balances.
Meeting 8 — Special Meeting (November 2017): The board reviewed and approved headcount increase authorizations, adding positions in regulatory affairs and commercial strategy functions. The board discussed the organizational growth trajectory and approved hiring plans consistent with PBI's expanding operational responsibilities. PBI's headcount at this point had grown to approximately 130 employees.
Meeting 9 — Q4 Regular Meeting (December 2017): The board reviewed full-year 2017 financial performance, including preliminary revenue and operating income figures. The board approved the year-end financial statements and authorized the Managing Director to sign the statutory financial statements on PBI's behalf. The board also approved CSA year-end cost-sharing reconciliation adjustments.
Meeting 10 — Special Meeting (December 2017): A second December meeting was convened to address two time-sensitive matters: (i) approval of a new distribution agreement for a Middle Eastern territory, the negotiation of which had been completed in November 2017; and (ii) a pricing decision for Veritaxol in a major EMEA market where a competitor had announced a price reduction.
B. 2018 Meetings (11 Meetings)
Meeting 11 — Q1 Regular Meeting (March 15, 2018)
Date: March 15, 2018
Location: 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland
Attendees: Full board present; PBI management team in attendance; PBI's Irish tax advisor, Ciarán Thornbury of Thornbury & Keogh, 22 Fitzwilliam Square, Dublin 2, participated for a portion of the meeting to address TCJA-related matters.
Agenda Items:
• Review of FY 2017 final audited results for PBI
• Presentation and approval of 2018 operating budget
• Determination of 2018 cost-sharing percentage under the CSA
• Discussion of the impact of the U.S. Tax Cuts and Jobs Act ("TCJA"), enacted December 22, 2017 and effective January 1, 2018, on intercompany arrangements, including the reduction of the U.S. federal corporate tax rate from 35% to 21% and the introduction of new provisions affecting CFCs (including GILTI under IRC § 951A and BEAT under IRC § 59A)
• Veritaxol pricing review across 68 non-Americas country markets
• Review of legacy compound portfolio performance
Key Decisions:
• The board approved PBI's 2018 operating budget. The cost-sharing percentage for 2018 was set at 39.6% of total anticipated R&D costs of $523.8 million, resulting in a projected cost-sharing payment of $207.42 million. The increase in the cost-sharing percentage from 38.2% in 2017 to 39.6% in 2018 reflected the growing share of reasonably anticipated benefits attributable to non-Americas territories, driven by Veritaxol and Imvara market expansion.
• The board received a detailed presentation from PBI's CFO and from Ciarán Thornbury regarding the potential impact of the TCJA on PBI's intercompany arrangements and transfer pricing structure. The board discussed the implications of the new GILTI provisions for PPC's U.S. tax position and the extent to which PBI's existing transfer pricing arrangements remained supportable under the revised U.S. tax regime. After discussion, the board concluded that no immediate changes to intercompany arrangements were warranted but directed management to monitor developments and report back at future meetings.
• The board conducted its annual comprehensive pricing review for Veritaxol across all 68 non-Americas country markets. PBI's commercial strategy team presented market-by-market pricing analyses, and the board approved pricing adjustments in multiple markets. The granularity and detail of this pricing review — covering 68 separate markets with individualized analyses — is strong evidence of PBI's active Exploitation function.
• The board reviewed legacy compound portfolio performance, noting that non-Americas net sales of legacy compounds totaled $814.6 million in 2017. The board discussed the expected decline trajectory for legacy compounds and the implications for PBI's revenue mix.
Meeting 12 — Special Meeting (April 19, 2018)
Date: April 19, 2018
Location: 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland
Attendees: Quorum of board present, including chair Aidan Naughton; PBI Head of Regulatory Affairs and Head of IT in attendance.
Agenda Items:
• Approval of new regulatory submissions for Imvara in five additional EMEA markets
• Capital expenditure approval for Dublin office expansion and technology infrastructure upgrades
Key Decisions:
• The board approved regulatory submission plans for Imvara in five EMEA markets, authorizing the associated expenditure and timelines. The Head of Regulatory Affairs presented the regulatory pathway and estimated timeline for each market, including anticipated interactions with local regulatory authorities.
• The board approved capital expenditure for expansion and technology upgrades to PBI's Dublin offices, including enhancements to PBI's regulatory information management system, commercial analytics platforms, and cybersecurity infrastructure. These investments supported PBI's ability to manage and control its commercial operations across 68 country markets.
Meeting 13 — Special Meeting (May 24, 2018)
Date: May 24, 2018
Location: 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland
Attendees: Full board present; Ciarán Thornbury of Thornbury & Keogh in attendance for the full meeting.
Agenda Items:
• Discussion of Knowledge Development box ("KDB") claims under Section 769R of the Taxes Consolidation Act 1997 (as amended by Finance Act 2015), providing a 6.25% effective tax rate on qualifying intellectual property income, applicable from FY 2016 forward
• Review of PBI's KDB compliance position and documentation
• Coordination with Thornbury & Keogh on KDB filing requirements
Key Decisions:
• The board received a comprehensive presentation from Mr. Thornbury on the requirements for claiming the Knowledge Development box, including the qualifying criteria for intellectual property assets, the nexus fraction calculation, and documentation requirements. The board reviewed PBI's qualifying IP income and the nexus fraction calculation for the relevant fiscal year.
• After deliberation, the board authorized PBI's finance team to finalize the KDB claim in coordination with Thornbury & Keogh and to maintain the documentation necessary to support the claim in the event of a Revenue Commissioners inquiry.
Meetings 14–21 — Remaining 2018 Meetings
The remaining eight meetings held during 2018 (Meetings 14 through 21) addressed the following principal topics. A complete listing is provided in Appendix A.
Meeting 14 — Special Meeting (June 2018): Pricing adjustments for Cerulon in rare-disease markets across EMEA, including orphan drug pricing considerations and patient access program design. The board reviewed competitive intelligence on competitor rare-disease therapies and approved pricing strategies designed to optimize both revenue and patient access.
Meeting 15 — Q2 Regular Meeting (June 2018): Comprehensive H1 2018 financial review; product-by-product revenue analysis; supply-chain quality review with PMI, including review of manufacturing deviation reports and corrective action status; update on distribution agreement negotiations.
Meeting 16 — Special Meeting (July 2018): Market response strategies in two key European markets where competitor products had launched or received regulatory approval. The board deliberated and approved competitive response plans, including pricing adjustments and enhanced marketing support. This meeting is notable for the documented deliberation among board members regarding the appropriate competitive response, with multiple alternatives considered and debated before a course of action was approved.
Meeting 17 — Special Meeting (August 2018): Regulatory milestone achievements, including EMA approval for an Imvara indication extension, and authorization of local-country marketing authorization submissions. The board also approved post-marketing commitments associated with the EMA approval.
Meeting 18 — Q3 Regular Meeting (September 2018): Nine-month financial review; budget reforecast; CSA cost-sharing reconciliation; review of legacy compound portfolio (non-Americas net sales of legacy compounds trending toward $762.3 million for FY 2018, down from $814.6 million in 2017); headcount review and approval of additional hires.
Meeting 19 — Special Meeting (October 2018): Negotiation and execution of new distribution agreements in two Africa/Middle East territories. The board reviewed and approved definitive agreement terms, including minimum purchase commitments, performance benchmarks, and termination provisions.
Meeting 20 — Q4 Regular Meeting (December 2018): Full-year 2018 performance review; approval of year-end financial statements; CSA year-end cost-sharing reconciliation and final payment calculation; approval of year-end headcount (PBI employee count reaching approximately 155 by end of 2018).
Meeting 21 — Special Meeting (December 2018): Year-end pricing review for three significant EMEA markets; coordination with Glenmore Bank Ireland plc on treasury management and foreign-exchange hedging for 2019; legacy compound licensing arrangements review.
C. 2019 Meetings (10 Meetings)
Meeting 22 — Q1 Regular Meeting (March 14, 2019)
Date: March 14, 2019
Location: 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland
Attendees: Full board present; PBI management team in attendance.
Agenda Items:
• Review of FY 2018 final audited results for PBI
• Presentation and approval of 2019 operating budget
• Determination of 2019 cost-sharing percentage under the CSA
• Discussion of Veritaxol global blockbuster trajectory and non-Americas growth projections
• Imvara non-Americas performance review and growth outlook
• Authorization of 2019 regulatory capital expenditure
Key Decisions:
• The board approved PBI's 2019 operating budget. The cost-sharing percentage for 2019 was set at 41.1% of total anticipated R&D costs of $561.2 million, resulting in a projected cost-sharing payment of $230.65 million. The continued increase in the cost-sharing percentage reflected the accelerating growth of PBI's non-Americas commercial operations relative to PPC's Americas operations.
• The board discussed Veritaxol's trajectory toward global blockbuster status, with combined global net sales projected to approach $3.12 billion by 2020. The non-Americas portion, managed by PBI, was projected at approximately $1.34 billion by 2020. The board deliberated on pricing and market-access strategies necessary to achieve these projections.
• The board reviewed Imvara non-Americas performance, which was projected to approach $790 million in non-Americas net sales by 2020, reflecting successful market expansion across EMEA and Asia-Pacific territories.
• The board authorized regulatory capital expenditure for 2019, including planned submissions in multiple jurisdictions and post-marketing studies.
Meeting 23 — Special Meeting (May 9, 2019)
Date: May 9, 2019
Location: 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland
Attendees: Quorum of board present; PBI commercial strategy team in attendance.
Agenda Items:
• Evaluation and approval of market entry into four additional country territories
• Review of competitive pricing intelligence across key EMEA markets
• Approval of revised Veritaxol pricing in specific EMEA markets
Key Decisions:
• The board evaluated market entry proposals for four additional territories, reviewing market size, patient population, competitive landscape, regulatory pathway, and distribution infrastructure for each. After deliberation, the board approved market entry for all four territories, subject to conditions including satisfactory distribution partner selection and regulatory submission planning.
• The board reviewed competitive pricing intelligence and approved revised Veritaxol pricing for several key EMEA markets. The pricing revisions were designed to respond to competitive dynamics and evolving reimbursement environments in those markets. The minutes specifically record that PBI's commercial strategy team developed these pricing recommendations based on local market analysis conducted in Dublin, and the board exercised its own judgment in approving them. This is significant evidence of PBI's independent pricing authority and its active Exploitation function.
Meetings 24–31 — Remaining 2019 Meetings
The remaining eight meetings held during 2019 (Meetings 24 through 31) addressed the following principal topics. A complete listing is provided in Appendix A.
Meeting 24 — Special Meeting (May 2019): Risk management review, including foreign-exchange exposure assessment and hedging strategy for 2019–2020, market access risks in specific jurisdictions facing government pricing reforms, and regulatory risk assessment for pipeline products. The board approved revised hedging parameters with Glenmore Bank Ireland plc.
Meeting 25 — Q2 Regular Meeting (June 2019): H1 2019 financial review; Cerulon non-Americas expansion update (non-Americas net sales projected to approach $280 million by 2020); supply-chain capacity planning discussions with PMI (which had grown to approximately 620 employees); review of manufacturing agreement performance metrics.
Meeting 26 — Special Meeting (July 2019): Regulatory dossier submissions across multiple non-Americas territories for both Veritaxol and Imvara indication extensions. The board approved filing strategies and associated expenditures.
Meeting 27 — Special Meeting (August 2019): Distribution agreement renewals in three EMEA territories. The board reviewed the performance of existing distribution partners, evaluated renewal terms, and approved definitive agreements.
Meeting 28 — Q3 Regular Meeting (September 2019): Nine-month financial review and budget reforecast; legacy compound phase-down management (non-Americas net sales of legacy compounds projected at $691.8 million for FY 2019, continuing the decline from $762.3 million in 2018 and $814.6 million in 2017); CSA cost-sharing reconciliation review; capital expenditure for regulatory compliance system enhancements.
Meeting 29 — Special Meeting (October 2019): The board reviewed a competitive landscape analysis for Imvara in two major EMEA markets where new competitor entries were anticipated. The board deliberated on proactive market defense strategies and approved a marketing investment plan.
Meeting 30 — Q4 Regular Meeting (December 2019): Full-year 2019 performance review and preliminary financial results; approval of year-end financial statements; CSA year-end cost-sharing reconciliation; year-end headcount review (PBI employee count reaching approximately 175).
Meeting 31 — Special Meeting (December 2019): End-of-year pricing review across multiple country markets; 2020 budget preview; preliminary discussion of strategic planning for the 2020–2022 period.